COMT and melanoma: Medication variables associated with melanoma risk were ever use of a dopamine agonist (HR, 1.18; 95% CI, 1.01–1.38) and ever use of a COMT inhibitor (HR, 0.76; 95% CI, 0.58–0.99) compared with no use.